Peritoneal Metastasis: Current Status and Treatment Options

Roth, Lilian; Russo, Linda; Ulugoel, Sima; Santos, Rafael Freire dos; Breuer, Eva; Gupta, Anurag; Lehmann, Kuno

doi:10.3390/cancers14010060

Cited by 23 publications

(17 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Colorectal peritoneal metastases present or develop in about 25% of patients with colorectal cancers ( 1 ). The prognosis of patients with colorectal peritoneal metastases is poor, and there is currently no established standard treatment ( 6 ). A previous study reported that 50% of patients with colorectal peritoneal metastasis are suitable for immunotherapy ( 26 ).…”

Section: Discussionmentioning

confidence: 99%

“…Although various approaches, such as extended resections, combination chemotherapy, i.p. chemotherapy, and immunotherapy, have been attempted, the prognosis of patients with peritoneal metastases remains poor, and there is no established standard treatment ( 6 ). Immune checkpoint blockade (ICB) has shown promising therapeutic efficacy in cancer therapy; however, it has been shown that peritoneal metastases are associated with a low response rate to ICB and poor clinical outcomes after ICB therapy ( 5 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Intraperitoneal injection of class A TLR9 agonist enhances anti–PD-1 immunotherapy in colorectal peritoneal metastases

Jiang¹,

Zhang²,

Li³

et al. 2022

JCI Insight

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Intraperitoneal injection of class A TLR9 agonist enhances anti–PD-1 immunotherapy in colorectal peritoneal metastases

Jiang¹,

Zhang²,

Li³

et al. 2022

JCI Insight

View full text Add to dashboard Cite

“…These strategies, including radical surgery and thermoperitoneal chemotherapy (HIPEC), showed surprisingly promising results and prolonged the survival time of patients with peritoneal metastasis. Because the therapeutic effect of PMCC has been greatly improved in recent years and the therapeutic concept is mainly based on active intervention rather than palliative treatment ( 29 ), although from the current research status, there is still a long way to go to achieve revolutionary therapeutic effect. Therefore, considerable efforts should be made to identify patients with PC at the earliest stages before further dissemination of PMCC.…”

Section: Discussionmentioning

confidence: 99%

Nomogram for prediction of peritoneal metastasis risk in colorectal cancer

Song¹,

Liu

Kong

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

ObjectivePeritoneal metastasis is difficult to diagnose using traditional imaging techniques. The main aim of the current study was to develop and validate a nomogram for effectively predicting the risk of peritoneal metastasis in colorectal cancer (PMCC).MethodsA retrospective case-control study was conducted using clinical data from 1284 patients with colorectal cancer who underwent surgery at the First Affiliated Hospital of Guangxi Medical University from January 2010 to December 2015. Least absolute shrinkage and selection operator (LASSO) regression was applied to optimize feature selection of the PMCC risk prediction model and multivariate logistic regression analysis conducted to determine independent risk factors. Using the combined features selected in the LASSO regression model, we constructed a nomogram model and evaluated its predictive value via receiver operating characteristic (ROC) curve analysis. The bootstrap method was employed for repeated sampling for internal verification and the discrimination ability of the prediction models evaluated based on the C-index. The consistency between the predicted and actual results was assessed with the aid of calibration curves.ResultsOverall, 96 cases of PMCC were confirmed via postoperative pathological diagnosis. Logistic regression analysis showed that age, tumor location, perimeter ratio, tumor size, pathological type, tumor invasion depth, CEA level, and gross tumor type were independent risk factors for PMCC. A nomogram composed of these eight factors was subsequently constructed. The calibration curve revealed good consistency between the predicted and actual probability, with a C-index of 0.882. The area under the curve (AUC) of the nomogram prediction model was 0.882 and its 95% confidence interval (CI) was 0.845–0.919. Internal validation yielded a C-index of 0.868.ConclusionWe have successfully constructed a highly sensitive nomogram that should facilitate early diagnosis of PMCC, providing a robust platform for further optimization of clinical management strategies.

show abstract

“…For colorectal cancer (CRC), it is still the fourth leading cause of cancer-related death worldwide ( 2 ), more than a hundred thousand new cases and fifty thousand deaths were estimated in 2021 ( 1 ). Genetic, environmental, epigenetic, and microbiological factors have been considered as the causing factors of CRC ( 3 ). However, molecular pathogenesis is still not fully clarified.…”

Section: Introductionmentioning

confidence: 99%

The Novel LncRNA WASH5P Inhibits Colorectal Cancer Carcinogenesis via Targeting AKT Signaling Pathway

et al. 2022

View full text Add to dashboard Cite

Emerging evidence has shown that long non-coding RNAs (lncRNAs) play an important role in colorectal cancer (CRC) carcinogenesis, so more specific mechanisms of key lncRNAs in CRC initiation and development are needed. Here, we evaluated the expression profiles of lncRNAs in CRC tissues and identified a novel lncRNA generated from the pseudogene Wiskott-Aldrich syndrome protein (WASP) family homolog 5, termed lncRNA WASH5P. However, the role and potential molecular mechanism of this novel lncRNA in diseases, including CRC carcinogenesis, is unknown. Our present study found that WASH5P was significantly downregulated in CRC cell lines and tissues compared with normal controls. The ectopic expression of WASH5P in CRC cells could significantly inhibit CRC cell proliferation, invasion, and migration. In addition, WASH5P could increase the expression of E-cadherin and decrease Vimentin expression. WASH5P-overexpressing CRC cells developed tumors more slowly in different mouse models. Meanwhile, the overexpression of WASH5P could significantly inhibit AKT activation via suppressing AKT phosphorylation. The treatment of PI3K/AKT (phosphatidlinositol 3-kinase /protein kinase B) signaling agonist 740Y-P rescued WASH5P-reduced AKT phosphorylation and abolished the inhibitory effects of WASH5P on cell viability, migration, and invasion. Moreover, 740Y-P restored the WASH5P-induced downregulation of p-AKT and vimentin and the upregulation of E-cadherin via Western blot. In summary, our findings suggested that the novel lncRNA WASH5P might be a potential candidate biomarker and therapeutic target that could inhibit CRC by repressing the AKT signaling pathway.

show abstract

Peritoneal Metastasis: Current Status and Treatment Options

Cited by 23 publications

References 88 publications

Intraperitoneal injection of class A TLR9 agonist enhances anti–PD-1 immunotherapy in colorectal peritoneal metastases

Intraperitoneal injection of class A TLR9 agonist enhances anti–PD-1 immunotherapy in colorectal peritoneal metastases

Nomogram for prediction of peritoneal metastasis risk in colorectal cancer

The Novel LncRNA WASH5P Inhibits Colorectal Cancer Carcinogenesis via Targeting AKT Signaling Pathway

Contact Info

Product

Resources

About